UNSPSC 51112514: Mafosfamide lysine

This classification denotes a nitrogen mustard compound with the molecular formula C9H19Cl2N2O5PS2.C6H14N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HAC3DQ8PMS, chemically known as cis-2-((2-(bis(2-chloroethyl)amino)tetrahydro-2h-1,3,2-oxazaphosphorin-4-yl)thio)ethane sulfonate p-oxide l-lysine, but more generally known as mafosfamide lysine, which bears US NIH Compound Identifier 5362268.

European Medicines Agency schedules mafosfamide lysine or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08635MIG. Most nations, for tariff purposes, schedule mafosfamide lysine under HS 29349990. SMILES: C1CO[P@@](=O)(N[C@H]1SCCS(=O)(=O)O)N(CCCL)CCCL.C(CCN)C[C@@H](C(=O)O)N.

UNSPSC 51112514 Mafosfamide lysine is a Commodity code representing a specific pharmaceutical product — a chemotherapy agent — that state and local health agencies procure for clinical use. The code reflects chemotherapy medications that state health systems, corrections departments, and public health authorities source through pharmacy benefit managers, group purchasing organizations, or direct manufacturer relationships to support oncology treatment programs and public health initiatives. State and local governments buy this product primarily as part of formulary management and pharmaceutical procurement operations within Medicaid programs, state employee health plans, corrections systems, and public hospital networks, where the medication supports cancer treatment protocols under established clinical guidelines and cost-containment strategies.

The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, seeking vendor capabilities and market intelligence regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The RFI solicits detailed information from potential vendors about their capacity to establish direct relationships between the state's pharmacy benefit program and pharmaceutical manufacturers, including experience with direct contracting for self-insured employers and health plans, flexibility to negotiate contracts using net pricing models without rebates, and capability to implement value-based or outcomes-based agreements. The RFI functions as a preliminary market-intelligence tool to inform the state's future procurement strategy before issuing a formal RFP with established financial and temporal parameters. No award value or budget range is identified at this stage, as Texas HHS is conducting foundational research on available solutions and vendor capabilities rather than committing to specific contract amounts.